CliffBio
biologic

Takhzyro

lanadelumab-flyo

Loss of exclusivityFebruary 2034projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameTakhzyro
Active ingredientlanadelumab-flyo
Strength300MG/2ML (150MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalFebruary 2022
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Takhzyro patent cliff — loss of exclusivity February 2034 | CliffBio